In a small double-blind study, Johns Hopkins researchers report that a substantial majority of people suffering cancer-related anxiety or depression found considerable relief for up to six months from a single large dose of psilocybin — the active compound in hallucinogenic “magic mushrooms.”
The researchers cautioned that the drug was given in tightly controlled conditions in the presence of two clinically trained monitors and said they do not recommend use of the compound outside of such a research or patient care setting.
The Johns Hopkins team released its study results, involving 51 adult patients, concurrently with researchers from New York University Langone Medical Center, who conducted a similarly designed study on 29 participants. Both studies are published in the Journal of Psychopharmacology on Dec. 1.
The Johns Hopkins group reported that psilocybin decreased clinician- and patient-rated depressed mood, anxiety and death anxiety, and increased quality of life, life meaning and optimism. Six months after the final session of treatment, about 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range. Eighty-three percent reported increases in well-being or life satisfaction. Some 67 percent of participants reported the experience as one of the top five meaningful experiences in their lives, and about 70 percent reported the experience as one of the top five spiritually significant lifetime events.
“The most interesting and remarkable finding is that a single dose of psilocybin, which lasts four to six hours, produced enduring decreases in depression and anxiety symptoms, and this may represent a fascinating new model for treating some psychiatric conditions,” says Roland Griffiths, Ph.D., professor of behavioral biology in the Departments of Psychiatry and Behavioral Sciences and of Neuroscience at the Johns Hopkins University School of Medicine. He notes that traditional psychotherapy offered to people with cancer, including behavioral therapy and antidepressants, can take weeks or even months, isn’t always effective, and in the case of some drugs, such as benzodiazepines, may have addictive and other troubling side effects.
Griffiths says his team’s new study grew out of a decade of research at Johns Hopkins on the effects of psilocybin in healthy volunteers, which found that psilocybin can consistently produce positive changes in mood, behavior and spirituality when administered to carefully screened and prepared participants. The study was designed to see if psilocybin could produce similar results in psychologically distressed cancer patients.
“A life-threatening cancer diagnosis can be psychologically challenging, with anxiety and depression as very common symptoms,” says Griffiths. “People with this kind of existential anxiety often feel hopeless and are worried about the meaning of life and what happens upon death.”
For the study, the investigators recruited 51 participants diagnosed with life-threatening cancers, most of which were recurrent or metastatic. They were chosen from a total of 566 individuals reached through flyers, web advertisements and physician referrals. Most participants had breast, upper digestive, GI, genitourinary or blood cancer, and each had been given a formal psychiatric diagnosis, including an anxiety or depressive disorder.
Half of the participants were female with an average age of 56. Ninety-two percent were white, 4 percent were African-American and 2 percent were Asian.
Each participant had two treatment sessions scheduled five weeks apart, one with a very low psilocybin dose (1 or3 milligrams per 70 kilograms) taken in a capsule and meant to act as a “control” placebo because the dose was too low to produce effects. In the other session, participants received a capsule with what is considered a moderate or high dose (22 or 30 milligrams per 70 kilograms).
To minimize expectancy effects, the participants and the staff members supervising the sessions were told that the participants would receive psilocybin on both sessions, but they did not know that all participants would receive one high and one low dose. Blood pressure and mood were monitored throughout the sessions. Two monitors aided participants during each session, encouraging them to lie down, wear an eye mask, listen to music through headphones and direct their attention on their inner experience. If anxiety or confusion arose, the monitors provided reassurance to the participants.
In addition to experiencing changes in visual perception, emotions and thinking, most participants reported experiences of psychological insight and often profound, deeply meaningful experiences of the interconnectedness of all people.
The researchers assessed each participant’s mood, attitude about life, behaviors and spirituality with questionnaires and structured interviews before the first session, seven hours after taking the psilocybin, five weeks after each session and six months after the second session. Immediately after the sessions, participants completed questionnaires assessing changes in visual, auditory and body perceptions; feelings of transcendence; changes in mood; and more.
Structured clinical interviews, such as the Hamilton Depression Rating Scale and the Hamilton Anxiety Rating Scale, and patient questionnaires, like the Beck Depression Inventory and the State-Trait Anxiety Inventory, assessed depression and anxiety. Other questionnaires assessed quality of life, death acceptance, meaningful existence, optimism and spirituality — generally defined as a search for the meaning of life and a connection to something bigger than one’s self. To measure the changes in attitudes, moods and behavior over time, the researchers administered a questionnaire that assessed negative or positive changes in attitudes about life, mood and behavior.
With regard to adverse effects, Griffiths says 15 percent of participants were nauseated or vomited, and one-third of participants experienced some psychological discomfort, such as anxiety or paranoia, after taking the higher dose. One-third of the participants had transient increases in blood pressure. A few participants reported headaches following the session.
“Before beginning the study, it wasn’t clear to me that this treatment would be helpful, since cancer patients may experience profound hopelessness in response to their diagnosis, which is often followed by multiple surgeries and prolonged chemotherapy,” says Griffiths. “I could imagine that cancer patients would receive psilocybin, look into the existential void and come out even more fearful. However, the positive changes in attitudes, moods and behavior that we documented in healthy volunteers were replicated in cancer patients.”
Up to 40 percent of people with cancer suffer from a mood disorder, according to the National Comprehensive Cancer Network.
Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K. Medicines and Healthcare Products Regulatory Authority. In general, the commentaries were supportive of the research and of using these drugs in a clinical setting as tools for psychiatry.
Taking a page from Jonathan Swift’s “Gulliver’s Travels”, a team of scientists has created malleable and microscopic self-assembling particles that can serve as the next generation of building blocks in the creation of synthetic materials.
“Our work turns the tiniest of particles from inflexible, Lego-like pieces into ones that can transform themselves into a range of shapes,” explains Stefano Sacanna, an assistant professor in NYU’s Department of Chemistry and the senior author of the paper, which appears in the journal Nature Communications. “With the ability to change their contours, these particles mimic alterations that occur in nature.”
The research focused on engineering particles a micrometer in width—about 1/200th the width of a strand of human hair.
Specifically, it aimed to enhance the adaptability of colloids—small particles suspended within a fluid medium. Such everyday items such as paint, milk, gelatin, glass, and porcelain are composed of colloidal dispersions, but it’s their potential to control the flow of light that has scientists focused on creating exotic colloidal geometries.
New York University (NYU) is a private, nonsectarian American research university based in New York City.
Founded in 1831, NYU is now one of the largest private universities in the United States. Its main campus is situated at Washington Square in Greenwich Village, and it also has campuses located overseas.
NYU was the founding member of the League of World Universities, an international organization consisting of rectors and presidents from urban universities across six continents. The league and its 47 representatives gather every two years to discuss global issues in education. L. Jay Oliva formed the organization in 1991 just after he was inaugurated president of New York University.
The Latest Updated Research News:
New York University (NYU) research articles from Innovation Toronto
- Tiny Transformers: Chemists Create Microscopic and Malleable Building Blocks – July 20, 2016
- Worm Infection Counters Inflammatory Bowel Disease by Drastically Changing Gut Microbiome – April 15, 2016
- Penn-Led Team Reprograms Social Behavior in Carpenter Ants Using Epigenetic Drugs – January 5, 2016
- Mapping the brain: Probes with tiny LEDs shed light on neural pathways – December 20, 2015
- Scientists Teach Machines to Learn Like Humans – December 14, 2015
- Shape Shifters: Demonstrating Tunable Phase Shifting – December 6, 2015
- Early evidence suggests hybrid cochlear implants may benefit millions with common form of hearing loss – August 9, 2015
- Tiny Robot Flies Like a Jellyfish
- A New, Flying Jellyfish-like Machine
- Research Paves Path for Hybrid NanoMaterials That Could Replace Human Tissue or Today’s Pills
- Are Microgrids the Answer to City-Disrupting Disasters?
- NYU-Poly Nano Scientists Reach the Holy Grail in Label-Free Cancer Marker Detection: Single Molecules
- For Solazyme, a Side Trip on the Way to Clean Fuel
- Scientists See Promise in Deep-Learning Programs
- Robotic Fish Research Swims into New Ethorobotics Waters
- Coming Soon: A Privately-Run City To Create Development In The Developing World
- The Workplace Benefits of Being Out of Touch
- Race Against the Machine
- Key Gene Found Responsible for Chronic Inflammation, Accelerated Aging and Cancer
- Controversy Flares Over Space-Based Solar Power Plans
- In The Battle Against Climate Change, Should We Engineer Humans Instead Of The Planet?
- Robot becomes a leader among fish
- Nanofiber breakthrough holds promise for medicine and microprocessors
- Flapping-wing aircraft gets closer to reality after breakthrough
- Could Dentists Double As Doctors?
- Something in the Way You Move: Cameras May Soon Recognize Criminals by Their Gait
- Game theory in practice
- New Glasses-Free 3-D Approach Could Work on Thin, Flexible Displays
- Self-Assembling “Cages” Trap Molecules
- Violinist Taps Artificial Intelligence to Interact with Her Unique Sound
- Will the Car of the Future Be Made from Coal Ash?
- Plan B for Energy: 8 Revolutionary Energy Sources
- Computer vision – Eye robot
- DIYers Turn Inspiration into Everything
- Fewer Degrees Of Separation Make Companies More Innovative, Creative
A team of scientists has developed an algorithm that captures our learning abilities, enabling computers to recognize and draw simple visual concepts that are mostly indistinguishable from those created by humans.
The work, which appears in the latest issue of the journal Science, marks a significant advance in the field—one that dramatically shortens the time it takes computers to “learn” new concepts and broadens their application to more creative tasks.
“Our results show that by reverse engineering how people think about a problem, we can develop better algorithms,” explains Brenden Lake, a Moore-Sloan Data Science Fellow at New York University and the paper’s lead author. “Moreover, this work points to promising methods to narrow the gap for other machine learning tasks.”